| 1/4 | US=16 / Tórax Dowell J, Gazdar AF, Shigematsu H, Herz J, Minna JD. Lung cancer biology: clinical and biologic implications of EGFR mutations in lung cancer. In: Pass HL, Carbone DP, Johnson DH, Minna JD, Turrisi III AT. Lung Cancer: principles and practice. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 172-7. ISBN 0-7817-4620-5. ONCOGENE; MUTACOES EGFR; NEOPLASIA PULMONAR; RECEPTOR DE TIROSINA QUINASE; INIBIDORES DE TIROSINA QUINASE; MUTACAO DE TIROSINA QUINASE |
| 2/4 | US=16 / Tórax Laskin J, Johnson DH. Novel therapeutic strategies: receptor tyrosine kinase inhibitors. In: Pass HL, Carbone DP, Johnson DH, Minna JD, Turrisi III AT. Lung Cancer: principles and practice. Philadelphia: Lippincott Williams & Wilkins, 2005. p. 725-33. ISBN 0-7817-4620-5. RECEPTORES DA FAMILIA EPH; INIBIDORES DE TIROSINA QUINASE; GENES ERBB-1; TERAPIA COMBINADA |
| 3/4 | US=25 / Biol/Mol Wright D. The science of cancer: cytotoxic chemotherapy. In: Gabriel J. The biology of cancer. 2nd ed. New Jersey: John Wiley & Sons, 2005. p. 45-53. ISBN 978-0-470-05759-9. QUIMIOTERAPIA CITOTOXICA; MECANISMO DE ACAO DA QUIMIOTERAPIA; INIBIDORES DE TIROSINA QUINASE |
| 4/4 | US=120 / Câncer Hajjar LA, Bittar CS, Santos MHH, Kalil Filho R. O acometimento cardiovascular no paciente com câncer. In: Hoff PMG. Tratado de oncologia. São Paulo: Atheneu, 2013. p. 1129-1138. ISBN 85-388-0312-6. CARDIOTOXICIDADE. DEFINICAO; COMPLICACOES CARDIOVASCULARES NO PACIENTE ONCOLOGICO; INSUFICIENCIA CARDIACA. DIAGNOSTICO; INIBIDORES DE TIROSINA QUINASE; CARDIOTOXICIDADE. PREVENCAO; INSUFICIENCIA CARDIACA EM ONCOLOGIA; ISQUEMIA MIOCARDICA. TRATAMENTO ANTINEOPLASICO; HIPERTENSAO ARTERIAL SISTEMICA. CANCER; ARRITMIAS. CANCER; TROMBOEMBOLISMO. CANCER |